SHARON REGIONAL HEALTH SYSTEM

Advanced Care Close to Home

Advanced Wound Recovery Center
Behavioral Health Services
Brain Attack/Stroke Center
Breast Care Center
Cancer Care Center
Chest Pain Emergency Center
Comprehensive Pain Management Center
Corporate Health Services
Diabetes Center
Ear, Nose, Throat & Hearing Center
Emergency Care Center
Express Care
Family Medicine Centers
HealthPLACE
Heart Institute
Home Health Agency
Hospice/Palliative Care
Hospital
Rehabilitation Services
School of Nursing
School of Radiography
Sports Medicine Services
Surgical Services
Transitional Care Unit
Women's Center

Facility Locations
Sharon
Hermitage
Mercer
Greenville
Brookfield, OH

Main Campus
740 East State Street
Sharon, PA 16146-3395
724-983-3911
www.sharonregional.com

John A. Zidansek
President & CEO

February 15, 2007

U.S. Nuclear Regulatory Commission
Materials Licensing Branch
Region 1
475 Allendale Road
King of Prussia, Pennsylvania 19406

K-7

03013670

RE: Materials License #37-01626-04
Sharon Regional Health System

Dear Sir or Madam,

We respectfully request the removal of the following physicians from our license:

- **Steven P. Karr, M.D.**
- **Adele Lipari, D.O.**
- **Barry E. Marchetto, M.D.**
- **Harish Panicker, M.D.**

We wish to add the following as authorized users for privileges under 10 CFR 35 parts 100, 200, 300 and 500:

- **Shanteri U. Nayak, M.D.**
- **Jonathan Potts, M.D.**

Both Dr. Nayak and Dr. Potts are on the NRC License # 37-01317-01 at Allegheny General Hospital in Pittsburgh, Pennsylvania and are authorized for parts 35.100, 35.200, and 35.300.

We also wish to add Frederick Borts, M.D. as an authorized user for 10 CFR 35.100, 35.200. Dr. Borts is on NRC License # 53-30546 at Kaiser Permanente Medical Center in Honolulu, Hawaii.

If you have any questions or require additional information, please do not hesitate to contact the undersigned.

Sincerely,

John R. Janoso, Jr.
Vice President/Chief Information Officer

JoAnne Esposito, B.A., R.T.R.
Director of Medical Imaging

140024

NMSS/RGN1 MATERIALS-002

ALLEGHENY GENERAL HOSPITAL
RADIOACTIVE MATERIAL USE PERMIT

This permit grants Akash Sharma, M.D. Authorized User status under NRC license 37-01317-01 and PA license PA-0031 and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties* Form, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

1. Akash Sharma, M.D.
Authorized User

2. 67
Permit Number

3. Nuclear Medicine
Department or Section

4. October 5, 2004
Approval Date

5. **Human Use Isotope Group**

X 35.100 X 35.200 X 35.300 ___35.400 ___35.500 ___35.600
___ 35.1000 (ENDOVASCULAR THERAPY) ___depleted U-235 shielding

6. **Authorized Use**

___ Group I ___ Group II ___ Group III

Group I isotopes (high radiotoxicity): beta $\geq$ 300 keV E_{avg}; gamma $\geq$ 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{avg}; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group III isotopes (low radiotoxicity): beta < 100 keV E_{avg}; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

7. **Restrictions:** NONE

Approval Signatures:

John Rehder, M.D. 10/5/04
Date
Chairman, Radiation Safety Committee
Allegheny General Hospital

Joseph G. Och, M.S. 10/6/04
Date
Radiation Safety Officer
Allegheny General Hospital

ALLEGHENY GENERAL HOSPITAL
RADIOACTIVE MATERIAL USE PERMIT

This permit grants Shanteri U. Nayak, M.D. Authorized User status and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties* Form, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212 or 3290 William Pitt Way, Building 9, Pittsburgh, PA 15238. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

1. Shanteri U. Nayak, M.D.
Authorized User

2. 38
Permit Number

3. Nuclear Medicine
Department or Section

4. April 17, 2001
Approval Date

5. Human Use - Isotope Groups 35.100, 35.200, 35.300
Authorized Use

6. ____ Group III ____ Group II ____ Group I

Group III isotopes (low radiotoxicity): beta < 100 keV E_{avg}; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{avg}; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group I isotopes (high radiotoxicity): beta ≥ 300 keV E_{avg}; gamma ≥ 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Approval Signatures:

G. W. Isaacs — 4/17/01

Gilbert Isaacs, M.D. — Date
Chairman, Radiation Safety Committee
Allegheny General Hospital

[signature] — 4/17/01

Joseph G. Och, M.S. — Date
Radiation Safety Officer
Allegheny General Hospital

ALLEGHENY GENERAL HOSPITAL
RADIOACTIVE MATERIAL USE PERMIT

This permit grants Jonathan Potts, M.D. Authorized User status and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties* Form, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212 or 3290 William Pitt Way, Building 9, Pittsburgh, PA 15238. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

1. Jonathan Potts, M.D.
Authorized User

2. 38
Permit Number

3. Nuclear Medicine
Department or Section

4. January 17, 1997
Approval Date

5. Human Use - Isotope Groups 35.100, 35.200, 35.300
Authorized Use

6. ____ Group III ____ Group II ____ Group I

Group III isotopes (low radiotoxicity): beta < 100 keV E_{avg}; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{avg}; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group I isotopes (high radiotoxicity): beta ≥ 300 keV E_{avg}; gamma ≥ 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Approval Signatures:

G. N. Isaacs — 8/22/00

Gilbert Isaacs, M.D.
Chairman, Radiation Safety Committee
Allegheny General Hospital

Date

Joseph G. Och, M.S.
Radiation Safety Officer
Allegheny General Hospital

Date

NRC FORM 374 U.S. NUCLEAR REGULATORY COMMISSION PAGE 1 OF 4 PAGES

Amendment No. 64

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Kaiser Foundation Hospital Diagnostic Imaging Department 2. 3288 Moanalua Road Honolulu, HI 96819	In accordance with letter dated September 1, 2004 3. License number 53-05379-01 is amended in its entirety to read as follows: 4. Expiration date November 30, 2004 5. Docket No. 030-03546 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. 3 curies (not to exceed 200 millicuries per container)
A. Iodine-125	D. Liquid as Iotrex™	D. As needed

9. Authorized use:

A. Medical use described in 10 CFR 35.100.
B. Medical use described in 10 CFR 35.200.
C. Medical use described in 10 CFR 35.300.
D. For brachytherapy use in the Proxima Therapeutics' GliaSite® Radiotherapy system.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 3288 Moanalua Road, Honolulu, Hawaii.

11. The Radiation Safety Officer for this license is Samuel Wu, M.D.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
53-05379-01

Docket or Reference Number
030-03546

Amendment No. 64

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
Decha Intaraprasong, M.D.	35.100, 35.200, 35.300
Chung Ta Hsin, M.D.	35.100, 35.200, 35.300
Katrena U. Wade Kennedy, M.D.	35.100, 35.200
Rickie A. Broadfoot, M.D.	35.100, 35.200
Allson M. Shibuya, M.D.	35.100, 35.200, 35.300
Stein Rafto, M.D.	35.100, 35.200
Peter Abcarian, M.D.	35.100, 35.200
Daniel C. Henshaw, M.D.	35.100, 35.200, 35.300
Bradford S. Burton, M.D.	35.100, 35.200
Frederick T. Borts, M.D.	35.100, 35.200
Felix Lee Song, M.D.	35.100, 35.200
Ramana B. Muthyala, M.D.	35.100, 35.200
Marie S. Noltakis, M.D.	35.100, 35.200
Samuel M. H. Wu, M.D.	35.100, 35.200, 35.300
John T. Watabe, M.D.	35.100, 35.200
Vincent Brown, M.D.	I-125
Paul DeMare, M.D.	I-125
Thanh Huynh, M.D.	I-125
Christina Liu, M.D.	I-125
Thomas G. Mahon, M.D.	35.100, 35.200
Steven W. Hong, M.D.	35.100, 35.200, 35.300

13. A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.

B. In the absence of a certificate from a transferor indicating that a leak test has been made within 6 months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

C. Sealed sources need not be leak tested if:

(i) they contain only hydrogen-3; or

(ii) they contain only a radioactive gas; or

(iii) the half-life of the isotope is 30 days or less; or

(iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
53-05379-01

Docket or Reference Number
030-03546

Amendment No. 64

(v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

D. The leak test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region IV, ATTN: Director, Division of Nuclear Materials Safety, 611 Ryan Plaza Drive, Suite 400, Arlington, Texas 76011-8064. The report shall specify the source involved, the test results, and corrective action taken.

E. The licensee is authorized to collect leak test samples for analysis by Health Physics Northwest. Alternatively, tests for leakage and/or contamination may be performed by persons specifically licensed by the Commission or an Agreement State to perform such services.

14. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee.

15. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

16. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

17. Notwithstanding the requirements in 10 CFR 35.400, the licensee may use Iodine-125 in the form of Iotrex™ liquid brachytherapy source in the Proxima Therapeutics' GliaSite® Radiotherapy system.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION	PAGE 4 of 4 PAGES
MATERIALS LICENSE **SUPPLEMENTARY SHEET**	License Number 53-05379-01
	Docket or Reference Number 030-03546
	Amendment No. 64

18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Letter dated May 25, 1994
B. Facsimile dated November 28, 1994
C. Letter dated December 16, 1994
D. Letter dated June 8, 1995
E. Letter dated March 21, 1996
F. Letter dated April 25, 1996
G. Letter dated May 6, 1996
H. Letter dated July 1, 1996
I. Letter dated March 13, 1997
J. Letter dated June 8, 1998
K. Letter dated December 28, 1998
L. Letter dated July 5, 2001
M. Letter dated June 10, 2002
N. Letter dated April 11, 2003
O. Letter dated July 3, 2003
P. Letter dated November 20, 2003

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: November 23, 2004

By: Rachel S. Browder

Rachel S. Browder, Health Physicist
Nuclear Materials Licensing Branch
Region IV
Arlington, Texas 76011